Bladder cancer - - Chromatography Online
Bladder cancer

The Column
Volume 8, Issue 21

A group of scientists in Taiwan1 has identified micro-particles within human urine that could be used for the non‑invasive diagnosis of bladder cancer. The occurrence of bladder cancer is rising every year, with the American Cancer Society 2 estimating that 73, 510 new cases of bladder cancer will be diagnosed by the end of 2012. The main methods of diagnosis are urine cytology and cytoscopy. Cytology is of low sensitivity when used as a diagnostic tool because it is poor at detecting low-grade bladder cancers, and cytoscopy is a highly invasive diagnostic procedure.

The team took urine samples from hernia patients (as a control) and bladder cancer patients and observed the differential expression of proteins within urine micro‑particles found in each of the samples. To do this, they utilized isotopic dimethylation labeling coupled with liquid chromatography–multiple reaction monitoring-mass spectrometry (LC–MRM-MS) to identify biomarkers within urinary micro-particles isolated from urine samples collected from hernia control patients and bladder cancer patients. 2,964 proteins were identified to be differentially expressed, present within the samples of either the controls or test subjects but not both, with 2058 novel proteins not previously reported. A total of 29 proteins were determined by statistical analysis to be differentially expressed at a level that made them potentially suitable to be biomarkers in bladder cancer diagnosis. The study quantified tumour-associated calcium transducer 2 (TACSTD2) within the raw urine specimens, confirming its potential use as a biomarker in diagnosis.

The identification of biomarkers has great potential in a clinical setting to reduce the method invasion and the discomfort to the patient in addition to reducing the cost of surveillance.

1. C-L. Chen et al, Journal of Proteome Research, (Accessed 30th of October 2012, www.pubs.acs.org).

2. American Cancer Society (Accessed 1st of November 2012, http://www.cancer.org/).

This story originally appeared in The Column. Click here to view that issue.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters
Global E-newsletters subscribe here:




 

LCGC COLUMNISTS 2014

Sample Prep Perspectives | Ronald E. Majors: Ron Majors, established authority on new column technologies, keeps readers up-to-date with new sample preparation trends in all branches of chromatography and reviews developments.
LATEST: UV Detector Problems


Perspectives in Modern HPLC | Michael W. Dong: Michael W. Dong is a senior scientist in Small Molecule Drug Discovery at Genentech in South San Francisco, California. He is responsible for new technologies, automation, and supporting late-stage research projects in small molecule analytical chemistry and QC of small molecule pharmaceutical sciences. LATEST: Superficially Porous Particles: Perspectives, Practices, and Trends


MS — The Practical Art | Kate Yu: Kate Yu brings her expertise in the field of mass spectrometry and hyphenated techniques to the pages of LCGC. In this column she examines the mass spectrometric side of coupled liquid and gas-phase systems. Troubleshooting-style articles provide readers with invaluable advice for getting the most from their mass spectrometers. LATEST: Radical Mass Spectrometry as a New Frontier for Bioanalysis


LC Troubleshooting | John Dolan: LC Troubleshooting sets about making HPLC methods easier to master. By covering the basics of liquid chromatography separations and instrumentation, John Dolan is able to highlight common problems and provide remedies for them. LATEST: Problems with Large-Molecule Separations


More LCGC Chromatography-Related Columnists>>

LCGC North America Editorial Advisory Board>>

LCGC Europe Editorial Advisory Board>>

LCGC Editorial Team Contacts>>


Source: The Column,
Click here